

Alessandra Carobbio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2233902/publications.pdf>

Version: 2024-02-01

111
papers

7,297
citations

57631

44
h-index

54797

84
g-index

113
all docs

113
docs citations

113
times ranked

5455
citing authors

#	ARTICLE	IF	CITATIONS
1	Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. <i>Leukemia</i> , 2013, 27, 1874-1881.	3.3	540
2	Development and validation of an International Prognostic Score of thrombosis in World Health Organizationâ€œessential thrombocythemia (IPSET-thrombosis). <i>Blood</i> , 2012, 120, 5128-5133.	0.6	461
3	Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 3179-3184.	0.8	441
4	Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. <i>Blood</i> , 2011, 117, 5857-5859.	0.6	376
5	Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. <i>Blood</i> , 2007, 109, 2310-2313.	0.6	295
6	Effect of Anakinra on Recurrent Pericarditis Among Patients With Colchicine Resistance and Corticosteroid Dependence. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 1906.	3.8	242
7	A prognostic model to predict survival in 867 World Health Organizationâ€œdefined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. <i>Blood</i> , 2012, 120, 1197-1201.	0.6	222
8	Thrombosis in primary myelofibrosis: incidence and risk factors. <i>Blood</i> , 2010, 115, 778-782.	0.6	216
9	A pilot study of the Histoneâ€œDeacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. <i>British Journal of Haematology</i> , 2010, 150, 446-455.	1.2	202
10	Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. <i>Blood Cancer Journal</i> , 2015, 5, e369-e369.	2.8	188
11	Leukocytosis and Risk Stratification Assessment in Essential Thrombocythemia. <i>Journal of Clinical Oncology</i> , 2008, 26, 2732-2736.	0.8	169
12	Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. <i>Haematologica</i> , 2011, 96, 315-318.	1.7	160
13	Risk Factors for the Development of Secondary Malignancy After High-Dose Chemotherapy and Autograft, With or Without Rituximab: A 20-Year Retrospective Follow-Up Study in Patients With Lymphoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 814-824.	0.8	151
14	Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. <i>Leukemia</i> , 2012, 26, 716-719.	3.3	149
15	Human platelet lysate allows expansion and clinical grade production of mesenchymal stromal cells from small samples of bone marrow aspirates or marrow filter washouts. <i>Bone Marrow Transplantation</i> , 2007, 40, 785-791.	1.3	148
16	The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2V617F. <i>Leukemia</i> , 2008, 22, 740-747.	3.3	141
17	Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?. <i>Blood</i> , 2009, 114, 759-763.	0.6	137
18	Masked polycythemia Vera (mPV): Results of an international study. <i>American Journal of Hematology</i> , 2014, 89, 52-54.	2.0	130

#	ARTICLE	IF	CITATIONS
19	PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics. <i>Annals of Oncology</i> , 2014, 25, 2433-2442.	0.6	119
20	In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. <i>Blood</i> , 2014, 124, 3021-3023.	0.6	112
21	Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis. <i>Blood Advances</i> , 2019, 3, 1729-1737.	2.5	105
22	Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia. <i>Blood</i> , 2008, 112, 3135-3137.	0.6	100
23	Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. <i>Blood</i> , 2012, 119, 2239-2241.	0.6	90
24	JAK2V617F allele burden and thrombosis: A direct comparison in essential thrombocythemia and polycythemia vera. <i>Experimental Hematology</i> , 2009, 37, 1016-1021.	0.2	89
25	The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600. <i>Annals of Oncology</i> , 2015, 26, 1980-1987.	0.6	88
26	Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients. <i>Blood Cancer Journal</i> , 2016, 6, e493-e493.	2.8	80
27	Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia. <i>Blood</i> , 2014, 124, 2611-2612.	0.6	79
28	Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV) Tj ETQq0 0 0 rgBTJ (Overlock, 10 Tf 50 : 2.2	2.2	79
29	Discriminating between essential thrombocythemia and masked polycythemia vera in <i>JAK2</i> mutated patients. <i>American Journal of Hematology</i> , 2014, 89, 588-590.	2.0	75
30	High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists. <i>Leukemia</i> , 2016, 30, 2032-2038.	3.3	75
31	Predicting the occurrence of embolic events: an analysis of 1456 episodes of infective endocarditis from the Italian Study on Endocarditis (SEI). <i>BMC Infectious Diseases</i> , 2014, 14, 230.	1.3	71
32	High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib. <i>Leukemia</i> , 2021, 35, 485-493.	3.3	70
33	Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis. <i>Blood</i> , 2012, 120, 569-571.	0.6	69
34	Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study. <i>Leukemia</i> , 2019, 33, 1996-2005.	3.3	67
35	Masked polycythemia vera diagnosed according to WHO and BCSH classification. <i>American Journal of Hematology</i> , 2014, 89, 199-202.	2.0	64
36	Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. <i>Haematologica</i> , 2014, 99, 916-921.	1.7	62

#	ARTICLE	IF	CITATIONS
37	Immunohistochemistry is highly sensitive and specific for the detection of NRASQ61R mutation in melanoma. <i>Modern Pathology</i> , 2015, 28, 487-497.	2.9	59
38	A reappraisal of the benefitâ€risk profile of hydroxyurea in polycythemia vera: A propensityâ€matched study. <i>American Journal of Hematology</i> , 2017, 92, 1131-1136.	2.0	57
39	Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria. <i>Blood</i> , 2010, 116, 1051-1055.	0.6	56
40	Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases. <i>Blood Cancer Journal</i> , 2018, 8, 112.	2.8	55
41	Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases. <i>American Journal of Hematology</i> , 2020, 95, 156-166.	2.0	53
42	Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis. <i>Leukemia</i> , 2013, 27, 2084-2086.	3.3	51
43	Leukocytosis as an important risk factor for arterial thrombosis in WHOâ€defined early/prefibrotic myelofibrosis: An international study of 264 patients. <i>American Journal of Hematology</i> , 2012, 87, 669-672.	2.0	49
44	A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera. <i>British Journal of Haematology</i> , 2014, 167, 541-546.	1.2	47
45	The effect of arterial hypertension on thrombosis in lowâ€risk polycythemia vera. <i>American Journal of Hematology</i> , 2017, 92, E5-E6.	2.0	45
46	Ruxolitinib for the prevention of thrombosis in polycythemia vera: a systematic review and meta-analysis. <i>Blood Advances</i> , 2020, 4, 380-386.	2.5	45
47	Cerebral vein thrombosis in patients with Philadelphiaâ€negative myeloproliferative neoplasms An European LeukemiaNet study. <i>American Journal of Hematology</i> , 2014, 89, E200-5.	2.0	42
48	Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia. <i>Haematologica</i> , 2010, 95, 1435-1438.	1.7	41
49	Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera. <i>Journal of Hematology and Oncology</i> , 2017, 10, 54.	6.9	41
50	Full-Right-Full-Left Split Liver Transplantation: The Retrospective Analysis of an Early Multicenter Experience Including Graft Sharing. <i>American Journal of Transplantation</i> , 2012, 12, 2198-2210.	2.6	36
51	Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis. <i>Blood Cancer Journal</i> , 2020, 10, 21.	2.8	35
52	Generating signals of drug-adverse effects from prescription databases and application to the risk of arrhythmia associated with antibacterials. <i>Pharmacoepidemiology and Drug Safety</i> , 2005, 14, 31-40.	0.9	34
53	Second cancers in MPN: Survival analysis from an international study. <i>American Journal of Hematology</i> , 2020, 95, 295-301.	2.0	34
54	Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients. <i>Leukemia</i> , 2021, 35, 2989-2993.	3.3	34

#	ARTICLE	IF	CITATIONS
55	Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study. <i>Blood Advances</i> , 2022, 6, 373-375.	2.5	34
56	Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis. <i>Haematologica</i> , 2019, 104, 2391-2399.	1.7	33
57	CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis. <i>Leukemia</i> , 2015, 29, 1209-1210.	3.3	31
58	Lymphoproliferative disorders in patients with chronic myeloproliferative neoplasms: A systematic review. <i>American Journal of Hematology</i> , 2018, 93, 698-703.	2.0	31
59	Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera. <i>Blood Cancer Journal</i> , 2022, 12, 28.	2.8	31
60	Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia. <i>American Journal of Hematology</i> , 2012, 87, 203-204.	2.0	29
61	A PROGNOSTIC MODEL to PREDICT SURVIVAL In WHO-DEFINED ESSENTIAL THROMBOCYTHEMIA: A STUDY by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and) Tj ETQq1 1 0.784314 cgBT /Overdoek 10.tif		
62	Diagnostic impact of the 2016 revised who criteria for polycythemia vera. <i>American Journal of Hematology</i> , 2017, 92, 417-419.	2.0	26
63	Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms. <i>Blood Cancer Journal</i> , 2018, 8, 25.	2.8	26
64	Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19. <i>Blood Cancer Journal</i> , 2021, 11, 21.	2.8	26
65	Telomere shortening in Ph-negative chronic myeloproliferative neoplasms: A biological marker of polycythemia vera and myelofibrosis, regardless of hydroxycarbamide therapy. <i>Experimental Hematology</i> , 2013, 41, 627-634.	0.2	22
66	No correlation of intensity of phlebotomy regimen with risk of thrombosis in polycythemia vera: evidence from European Collaboration on Low-Dose Aspirin in Polycythemia Vera and Cytoreductive Therapy in Polycythemia Vera clinical trials. <i>Haematologica</i> , 2017, 102, e219-e221.	1.7	21
67	Thrombosis in myeloproliferative neoplasms during cytoreductive and antithrombotic drug treatment. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12657.	1.0	21
68	Incidence of solid tumors in polycythemia vera treated with phlebotomy with or without hydroxyurea: ECLAP follow-up data. <i>Blood Cancer Journal</i> , 2018, 8, 5.	2.8	20
69	Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO criteria and stratified by calendar period of diagnosis. <i>American Journal of Hematology</i> , 2015, 90, 434-437.	2.0	19
70	A multistate model of survival prediction and event monitoring in prefibrotic myelofibrosis. <i>Blood Cancer Journal</i> , 2020, 10, 100.	2.8	19
71	Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study. <i>Blood</i> , 2020, 135, 381-386.	0.6	18
72	<i>ASXL1</i> mutations in primary and secondary myelofibrosis. <i>British Journal of Haematology</i> , 2012, 156, 404-407.	1.2	17

#	ARTICLE	IF	CITATIONS
73	The rate of transformation from JAK2-mutated ET to PV is influenced by an accurate WHO-defined clinico-morphological diagnosis. <i>Leukemia</i> , 2015, 29, 992-993.	3.3	16
74	Innovative haematological parameters for early diagnosis of sepsis in adult patients admitted in intensive care unit. <i>Journal of Clinical Pathology</i> , 2018, 71, 330-335.	1.0	15
75	Outcome of patients activating an unrelated donor search: the impact of transplant with reduced intensity conditioning in a large cohort of consecutive high-risk patients. <i>Leukemia</i> , 2012, 26, 1779-1785.	3.3	14
76	ACE inhibitors and cytoreductive therapy in polycythemia vera. <i>Blood</i> , 2017, 129, 1226-1227.	0.6	14
77	Cerebral venous thrombosis and myeloproliferative neoplasms: A three-center study of 74 consecutive cases. <i>American Journal of Hematology</i> , 2021, 96, 1580-1586.	2.0	13
78	Essential thrombocythemia with high hemoglobin levels according to the revised WHO classification. <i>Leukemia</i> , 2014, 28, 2092-2094.	3.3	12
79	Acute and Subacute Outcome Predictors in Moderate and Severe Traumatic Brain Injury: A Retrospective Monocentric Study. <i>World Neurosurgery</i> , 2019, 128, e531-e540.	0.7	11
80	Cerebral Vein Thrombosis In Patients With Myeloproliferative Neoplasms. <i>Blood</i> , 2013, 122, 4068-4068.	0.6	10
81	Long-term follow-up of recovered MPN patients with COVID-19. <i>Blood Cancer Journal</i> , 2021, 11, 115.	2.8	9
82	A short low-dose imatinib trial allows rapid identification of responsive patients in hypereosinophilic syndromes. <i>British Journal of Haematology</i> , 2009, 147, 681-685.	1.2	8
83	Direct Oral Anticoagulants for Myeloproliferative Neoplasms (MPN-DOACs): Results from an International Study on 442 Patients. <i>Blood</i> , 2020, 136, 42-43.	0.6	8
84	Second versus first wave of COVID-19 in patients with MPN. <i>Leukemia</i> , 2022, 36, 897-900.	3.3	7
85	Survival and Risk of Leukemic transformation in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study on 1,104 Patients. <i>Blood</i> , 2010, 116, 457-457.	0.6	6
86	Three-month mortality in permanently bedridden medical non-oncologic patients. The BECLAP study (permanently BEdridden, creatinine CLearance, albumin, previous hospital admissions study). <i>European Journal of Internal Medicine</i> , 2020, 72, 60-66.	1.0	5
87	Leukocytosis and thrombosis in polycythemia vera: can clinical trials settle the debate?. <i>Blood Advances</i> , 2019, 3, 3951-3952.	2.5	4
88	Echocardiographic Outflow Pump Ramp Test in Centrifugal-Flow Left Ventricular Assist Device. <i>International Journal of Artificial Organs</i> , 2017, 40, 128-131.	0.7	3
89	Response: Thrombocytosis in low-risk ET patients. <i>Blood</i> , 2008, 112, 3526-3527.	0.6	2
90	Frequency of Thrombosis Is Higher in MPN Patients Who Develop Second Cancer Than in Controls. <i>Blood</i> , 2019, 134, 4170-4170.	0.6	2

#	ARTICLE	IF	CITATIONS
91	The Interaction between IPSS Score and JAK2 Mutation Identifies Patients at Different Vascular Risk in Primary Myelofibrosis. <i>Blood</i> , 2021, 138, 236-236.	0.6	2
92	Symptom Burden in "Low Risk PV" Frequently Is Problematic and May Justify Earlier Intervention with Cytoreductive Therapy: An MPN-QOL Study Group Study. <i>Blood</i> , 2020, 136, 47-48.	0.6	2
93	Prolonged QRS associated with left bundle branch conduction defect is a prognostic red flag in asymptomatic patients at risk for heart failure (ACCF/AHA stages A and B): Insights from the DAVID-Berg study. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 2326-2329.	0.8	1
94	Response to: Ruxolitinib withdrawal due to the COVID-19. <i>Leukemia</i> , 2021, 35, 1219-1219.	3.3	1
95	Risk Factors for Secondary Cancer in a Case-Control Study on 1,259 Patients with Myeloproliferative Neoplasms. <i>Blood</i> , 2018, 132, 4279-4279.	0.6	1
96	Thrombosis in Primary Myelofibrosis: Incidence and Risk Factors.. <i>Blood</i> , 2009, 114, 2915-2915.	0.6	1
97	Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasms: A Study of the AGIMM & IWG-MRT Groups in 519 Subjects. <i>Blood</i> , 2014, 124, 3163-3163.	0.6	1
98	Telomere Length In Ph - Negative Chronic Myeloproliferative Neoplasms: It Is Reduced According to JAK2 V617F Mutation Allele Burden and It Is Not Affected by Cytoreductive Treatment with Hydroxyurea. <i>Blood</i> , 2010, 116, 1975-1975.	0.6	1
99	Neutrophil-to-Lymphocyte Ratio (NLR) Is a Risk Factor for Venous Thrombosis in Polycythemia Vera. <i>Blood</i> , 2021, 138, 1499-1499.	0.6	1
100	Leukocytosis and Risk Stratification Assessment in Essential Thrombocythemia.. <i>Blood</i> , 2007, 110, 681-681.	0.6	0
101	Similar Rate of Thrombosis in Essential Thrombocythemia and Polycythemia Vera Patients after Stratification for JAK2 V617F Allele Burden.. <i>Blood</i> , 2008, 112, 1745-1745.	0.6	0
102	High-Sensitivity C-Reactive Protein (hs-CRP) and Pentraxin 3 (PTX3) Are Increased in Essential Thrombocythemia and Polycythemia Vera.. <i>Blood</i> , 2009, 114, 1911-1911.	0.6	0
103	Changes of JAK2 V617F Allele Burden Over Time in Patients with Polycythemia Vera or Essential Thrombocythemia: A Retrospective Study of 172 Patients.. <i>Blood</i> , 2009, 114, 1892-1892.	0.6	0
104	Risk Factors for Thrombosis in WHO-Defined Early/Prefibrotic Myelofibrosis: An International Study of 264 Patients,. <i>Blood</i> , 2011, 118, 3846-3846.	0.6	0
105	Sensitivity and Specificity of Laboratory Parameters to Detect Early/Prefibrotic Myelofibrosis in 857 Patients with Essential Thrombocythemia. A Diagnostic Algorithm. <i>Blood</i> , 2011, 118, 5148-5148.	0.6	0
106	Masked Polycythemia Vera (mPV): Results Of An International Study. <i>Blood</i> , 2013, 122, 1581-1581.	0.6	0
107	Abstract 5604: PD-L1 expression identifies a subpopulation of melanoma cells characterized by enhanced invasiveness and aggressiveness. , 2014, , .		0
108	Calreticulin Mutation Does Not Modify the International Prognostic Score for Predicting the Risk of Thrombosis Among 1,150 Patients with Essential Thrombocythemia. <i>Blood</i> , 2014, 124, 404-404.	0.6	0

#	ARTICLE	IF	CITATIONS
109	Practice-Relevant Revision of Ipset-Thrombosis Based on 1019 Patients with WHO-Defined Essential Thrombocythemia. <i>Blood</i> , 2015, 126, 4055-4055.	0.6	0
110	Validation of the International Prognostic Score for Thrombosis in Essential Thrombocythemia (IPSET) in Patients with Pre-Fibrotic Primary Myelofibrosis. <i>Blood</i> , 2019, 134, 1657-1657.	0.6	0
111	Second <i><i>Versus</i></i> First Wave of COVID-19 in Patients with MPN. <i>Blood</i> , 2021, 138, 315-315.	0.6	0